Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GTPase Activity and Neuronal Toxicity of Parkinson's Disease–Associated LRRK2 Is Regulated by ArfGAP1
Klodjan Stafa, Alžbeta Trančíková, Philip J. Webber, et al.
PLoS Genetics (2012) Vol. 8, Iss. 2, pp. e1002526-e1002526
Open Access | Times Cited: 129

Showing 26-50 of 129 citing articles:

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
Jean‐Marc Taymans, Elisa Greggio
Current Neuropharmacology (2016) Vol. 14, Iss. 3, pp. 214-225
Open Access | Times Cited: 73
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration
Elpida Tsika, Meghna Kannan, Caroline S. Foo, et al.
Neurobiology of Disease (2014) Vol. 71, pp. 345-358
Open Access | Times Cited: 73
GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
Marian Blanca Ramírez, Antonio Jesús Lara Ordóñez, Elena Fdez, et al.
Human Molecular Genetics (2017) Vol. 26, Iss. 14, pp. 2747-2767
Open Access | Times Cited: 73
The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease
Hardy J. Rideout, Leonidas Stefanis
Neurochemical Research (2013) Vol. 39, Iss. 3, pp. 576-592
Closed Access | Times Cited: 72
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins
Mark S. Moehle, João Paulo Lima Daher, Travis D. Hull, et al.
Human Molecular Genetics (2015) Vol. 24, Iss. 15, pp. 4250-4267
Open Access | Times Cited: 72
The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A
Pilar Rivero-Ríos, María Romo-Lozano, Jesús Madero‐Pérez, et al.
Journal of Biological Chemistry (2019) Vol. 294, Iss. 13, pp. 4738-4758
Open Access | Times Cited: 68
Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease
Mattia Volta, Austen J. Milnerwood, Matthew J. Farrer
The Lancet Neurology (2015) Vol. 14, Iss. 10, pp. 1054-1064
Closed Access | Times Cited: 65
Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease
Juan I. Young, Sathesh K. Sivasankaran, Lily Wang, et al.
Neurology Genetics (2019) Vol. 5, Iss. 4
Open Access | Times Cited: 65
Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting
Erin T. Williams, Liliane Glauser, Elpida Tsika, et al.
Human Molecular Genetics (2018) Vol. 27, Iss. 18, pp. 3189-3205
Open Access | Times Cited: 63
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity
An Phu Tran Nguyen, Elpida Tsika, Kaela Kelly, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 29, pp. 17296-17307
Open Access | Times Cited: 53
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
Yulan Xiong, Jianzhong Yu
Trends in Molecular Medicine (2024) Vol. 30, Iss. 10, pp. 982-996
Closed Access | Times Cited: 7
Mechanisms of LRRK2-Mediated Neurodegeneration
Elpida Tsika, Darren J. Moore
Current Neurology and Neuroscience Reports (2012) Vol. 12, Iss. 3, pp. 251-260
Closed Access | Times Cited: 63
Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity
Jonathon Nixon‐Abell, Daniel C. Berwick, Simone Grannò, et al.
Frontiers in Molecular Neuroscience (2016) Vol. 9
Open Access | Times Cited: 59
Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications
Iakov N. Rudenko, Mark Cookson
Neurotherapeutics (2014) Vol. 11, Iss. 4, pp. 738-750
Open Access | Times Cited: 58
Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity
An Phu Tran Nguyen, Darren J. Moore
Advances in neurobiology (2017), pp. 71-88
Open Access | Times Cited: 56
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21WAF1/CIP1 expression
Dong Hwan Ho, Hye Jung Kim, Jisun Kim, et al.
Molecular Brain (2015) Vol. 8, Iss. 1
Open Access | Times Cited: 55
A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity
Julien Dusonchet, Hu Li, Maria Guillily, et al.
Human Molecular Genetics (2014) Vol. 23, Iss. 18, pp. 4887-4905
Open Access | Times Cited: 54
Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation
Md. Shariful Islam, Darren J. Moore
Biochemical Society Transactions (2017) Vol. 45, Iss. 1, pp. 163-172
Open Access | Times Cited: 52
P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity
Alexia F. Kalogeropulou, Jing Zhao, Marc Bolliger, et al.
Biochemical Journal (2018) Vol. 475, Iss. 7, pp. 1271-1293
Open Access | Times Cited: 50
Contribution of GTPase activity toLRRK2-associated Parkinson disease
Elpida Tsika, Darren J. Moore
Small GTPases (2013) Vol. 4, Iss. 3, pp. 164-170
Open Access | Times Cited: 53
The GTPase function of LRRK2
Jean‐Marc Taymans
Biochemical Society Transactions (2012) Vol. 40, Iss. 5, pp. 1063-1069
Closed Access | Times Cited: 52
Lrrk regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp
Chin‐Hsien Lin, Hsun Li, Yi‐Nan Lee, et al.
The Journal of Cell Biology (2015) Vol. 210, Iss. 3, pp. 471-483
Open Access | Times Cited: 48
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases
Adamantios Mamais, M. Snehith Raja, Claudia Manzoni, et al.
Neurobiology of Disease (2013) Vol. 58, pp. 183-190
Open Access | Times Cited: 47
LRRK2 enhances Nod1/2-mediated inflammatory cytokine production by promoting Rip2 phosphorylation
Ruiqing Yan, Zhihua Liu
Protein & Cell (2016) Vol. 8, Iss. 1, pp. 55-66
Open Access | Times Cited: 45
Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson’s Disease
Katharina E. Rosenbusch, Arjan Kortholt
Parkinson s Disease (2016) Vol. 2016, pp. 1-8
Open Access | Times Cited: 41

Scroll to top